The dioxin receptor has tumor suppressor activity in melanoma growth and metastasis

Carcinogenesis

Volumn 34, Issue 12, 2013, Pages 2683-2693

  Contador Troca, María ^a   Alvarez Barrientos, Alberto ^a   Barrasa, Eva ^a   Rico Leo, Eva M ^a   Catalina Fernández, Inmaculada ^b   Menacho Márquez, Mauricio ^c   Bustelo, Xosé R ^c   García Borrón, José C ^d   Gómez Durán, Aurea ^b   Sáenz Santamaría, Javier ^b   Fernández Salguero, Pedro M ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b HOSPITAL INFANTA CRISTINA   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d UNIVERSITY OF MURCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; BETA1 INTEGRIN; CAVEOLIN 1; MOLECULAR MARKER; SHORT HAIRPIN RNA;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL INTERACTION; CELL MIGRATION; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; LUNG METASTASIS; MELANOMA CELL; MELANOMA METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROMA CELL; TUMOR GROWTH; TUMOR INVASION;

ANIMALS; ANTIGENS, CD29; CARCINOGENESIS; CAVEOLINS; CELL LINE, TUMOR; CELL MOVEMENT; FIBROBLASTS; HUMANS; LUNG NEOPLASMS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; RECEPTORS, ARYL HYDROCARBON; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84889072389     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt248     Document Type: Article

References (49)

1. Furness,S.G. et al. (2007) The dioxin (aryl hydrocarbon) receptor as a model for adaptive responses of bHLH/PAS transcription factors. FEBS Lett., 581, 3616-3625.
2. Roman,A.C. et al. (2012) The aryl hydrocarbon receptor regulates cell adhesion and migration by interacting with oncogene and growth factor-dependent signaling. In Pohjanvirta,R. (ed) The AH Receptor in Biology and Toxicology. John Wiley & Sons, New York, NY, pp. 485-497.
3. Esser,C. et al. (2009) The aryl hydrocarbon receptor in immunity. Trends Immunol., 30, 447-454.
4. Barouki,R. et al. (2007) The aryl hydrocarbon receptor, more than a xenobiotic- interacting protein. FEBS Lett., 581, 3608-3615.
5. Moennikes,O. et al. (2004) A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res., 64, 4707-4710.
6. Andersson,P. et al. (2002) A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. Proc. Natl Acad. Sci. USA, 99, 9990-9995.
7. Hall,J.M. et al. (2010) Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation. Mol. Endocrinol., 24, 359-369.
8. Gluschnaider,U. et al. (2010) beta-TrCP inhibition reduces prostate cancer cell growth via upregulation of the aryl hydrocarbon receptor. PLoS One, 5, e9060.
9. Fan,Y. et al. (2010) The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Res., 70, 212-220.
10. Kawajiri,K. et al. (2009) Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands. Proc. Natl Acad. Sci. USA, 106, 13481-13486.
11. Mulero-Navarro,S. et al. (2006) The dioxin receptor is silenced by promoter hypermethylation in human acute lymphoblastic leukemia through inhibition of Sp1 binding. Carcinogenesis, 27, 1099-1104.
12. Carvajal-Gonzalez,J.M. et al. (2009) The dioxin receptor regulates the constitutive expression of the vav3 proto-oncogene and modulates cell shape and adhesion. Mol. Biol. Cell, 20, 1715-1727.
13. Mulero-Navarro,S. et al. (2005) Immortalized mouse mammary fibroblasts lacking dioxin receptor have impaired tumorigenicity in a subcutaneous mouse xenograft model. J. Biol. Chem., 280, 28731-28741.
14. Roman,A.C. et al. (2009) Dioxin receptor deficiency impairs angiogenesis by a mechanism involving VEGF-A depletion in the endothelium and transforming growth factor-beta overexpression in the stroma. J. Biol. Chem., 284, 25135-25148.
15. Carvajal-Gonzalez,J.M. et al. (2009) Loss of dioxin-receptor expression accelerates wound healing in vivo by a mechanism involving TGFbeta. J. Cell Sci., 122(Pt 11), 1823-1833.
16. Leiter,U. et al. (2004) The natural course of cutaneous melanoma. J. Surg. Oncol., 86, 172-178.
17. Balch,C.M. et al. (2004) An evidence-based staging system for cutaneous melanoma. CA. Cancer J. Clin., 54, 131-49; quiz 182.
18. Mellman,I. et al. (2011) Cancer immunotherapy comes of age. Nature, 480, 480-489.
19. Gkalpakiotis,S. et al. (2010) Quantitative detection of melanoma-associated antigens by multimarker real-time RT-PCR for molecular staging: results of a 5 years study. Exp. Dermatol., 19, 994-999.
20. Ribas,A. et al. (2011) Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial. Clin. Cancer Res., 17, 2987-2996.
21. Davies,H. et al. (2002) Mutations of the BRAF gene in human cancer. Nature, 417, 949-954.
22. Braeuer,R.R. et al. (2011) Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment. Semin. Cancer Biol., 21, 83-88.
23. Fernandez-Salguero,P. et al. (1995) Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science, 268, 722-726.
24. Rico-Leo,E.M. et al. (2013) Dioxin receptor expression inhibits basal and transforming growth factor β-induced epithelial-to-mesenchymal transition. J. Biol. Chem., 288, 7841-7856.
25. Rossi,L. et al. (2011) Hematopoietic stem cell characterization and isolation. Methods Mol. Biol., 750, 47-59.
26. Rey-Barroso,J. et al. (2013) The dioxin receptor controls β1 integrin activation in fibroblasts through a Cbp-Csk-Src pathway. Cell Signal., 25, 848-859.
27. Torres,V.A. et al. (2007) E-cadherin is required for caveolin-1-mediated downregulation of the inhibitor of apoptosis protein survivin via reduced betacatenin- Tcf/Lef-dependent transcription. Mol. Cell. Biol., 27, 7703-7717.
28. Pinon,P. et al. (2011) Integrins: versatile receptors controlling melanocyte adhesion, migration and proliferation. Pigment Cell Melanoma Res., 24, 282-294.
29. Trimmer,C. et al. (2010) CAV1 inhibits metastatic potential in melanomas through suppression of the integrin/Src/FAK signaling pathway. Cancer Res., 70, 7489-7499.
30. Fukunaga-Kalabis,M. et al. (2010) Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene, 29, 6115-6124.
31. Quintana,E. et al. (2008) Efficient tumour formation by single human melanoma cells. Nature, 456, 593-598.
32. Farnie,G. et al. (2007) Mammary stem cells and breast cancer-role of Notch signalling. Stem Cell Rev., 3, 169-175.
33. Pohjanvirta,R. (2012) The AH Receptor in Biology and Toxicology. John Wiley & Sons, New York, NY.
34. Pecina-Slaus,N. et al. (2007) E-cadherin and beta-catenin expression patterns in malignant melanoma assessed by image analysis. J. Cutan. Pathol., 34, 239-246.
35. Tucci,M.G. et al. (2007) Involvement of E-cadherin, beta-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma. Br. J. Dermatol., 157, 1212-1216.
36. Capozza,F. et al. (2012) Genetic ablation of Cav1 differentially affects melanoma tumor growth and metastasis in mice: role of Cav1 in Shh heterotypic signaling and transendothelial migration. Cancer Res., 72, 2262-2274.
37. Urra,H. et al. (2012) Caveolin-1-enhanced motility and focal adhesion turnover require tyrosine-14 but not accumulation to the rear in metastatic cancer cells. PLoS One, 7, e33085.
38. Arpaia,E. et al. (2012) The interaction between caveolin-1 and Rho- GTPases promotes metastasis by controlling the expression of alpha5- integrin and the activation of Src, Ras and Erk. Oncogene, 31, 884-896.
39. Thiery,J.P. et al. (2009) Epithelial-mesenchymal transitions in development and disease. Cell, 139, 871-890.
40. Zhao,S. et al. (2012) Activation of the aryl hydrocarbon receptor represses mammosphere formation in MCF-7 cells. Cancer Lett., 317, 192-198.
41. Boitano,A.E. et al. (2010) Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science, 329, 1345-1348.
42. Gomez-Duran,A. et al. (2009) Fitting a xenobiotic receptor into cell homeostasis: how the dioxin receptor interacts with TGFbeta signaling. Biochem. Pharmacol., 77, 700-712.
43. Straussman,R. et al. (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature, 487, 500-504.
44. Quintana,F.J. et al. (2008) Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature, 453, 65-71.
45. Veldhoen,M. et al. (2008) The aryl hydrocarbon receptor links TH17-cellmediated autoimmunity to environmental toxins. Nature, 453, 106-109.
46. Platten,M. et al. (2012) Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res., 72, 5435-5440.
47. Adams,S. et al. (2012) The kynurenine pathway in brain tumor pathogenesis. Cancer Res., 72, 5649-5657.
48. Bergander,L. et al. (2003) Characterization of in vitro metabolites of the aryl hydrocarbon receptor ligand 6-formylindolo[3,2-b]carbazole by liquid chromatography-mass spectrometry and NMR. Drug Metab. Dispos., 31, 233-241.
49. Wang,T. et al. (2011) Activation of the aryl hydrocarbon receptor by TCDD inhibits mammary tumor metastasis in a syngeneic mouse model of breast cancer. Toxicol. Sci., 124, 291-298.